Report cover image

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 127 Pages
SKU # APRC20542799

Description

Summary

According to APO Research, The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Post-Polycythemia Vera Myelofibrosis (PPV-MF) include Novartis AG, Merck & Co Inc, AbbVie Inc, Sun Pharma Advanced Research Company Ltd, Promedior Inc, NS Pharma Inc, MEI Pharma Inc, MedImmune LLC and JW Pharmaceutical Corp, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Post-Polycythemia Vera Myelofibrosis (PPV-MF), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Post-Polycythemia Vera Myelofibrosis (PPV-MF).
The Post-Polycythemia Vera Myelofibrosis (PPV-MF) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Company

Novartis AG
Merck & Co Inc
AbbVie Inc
Sun Pharma Advanced Research Company Ltd
Promedior Inc
NS Pharma Inc
MEI Pharma Inc
MedImmune LLC
JW Pharmaceutical Corp
Italfarmaco SpA
Incyte Corp
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
CTI BioPharma Corp
Celgene Corp
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Type

Idelalisib
Givinostat
Glasdegib
Durvalumab
IMG-7289
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application

Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application

Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Polycythemia Vera Myelofibrosis (PPV-MF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Post-Polycythemia Vera Myelofibrosis (PPV-MF) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

127 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Idelalisib
2.2.3 Givinostat
2.2.4 Glasdegib
2.2.5 Durvalumab
2.2.6 IMG-7289
2.2.7 Others
2.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospital
2.3.3 Clinic
2.3.4 Others
2.4 Assumptions and Limitations
3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Breakdown Data by Type
3.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Type (2020-2025)
3.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Type (2026-2031)
4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Breakdown Data by Application
4.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Application (2020-2025)
4.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Perspective (2020-2031)
5.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Growth Trends by Region
5.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Region (2020-2025)
5.2.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Region (2026-2031)
5.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Dynamics
5.3.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
5.3.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Drivers
5.3.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Challenges
5.3.4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players by Revenue
6.1.1 Global Top Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players by Revenue (2020-2025)
6.1.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Players (2020-2025)
6.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Post-Polycythemia Vera Myelofibrosis (PPV-MF) Head Office and Area Served
6.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players, Product Type & Application
6.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Manufacturers Established Date
6.6 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
7.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
7.4 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
8.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
8.4 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
9.2 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
9.4 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
10.2 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
10.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2020-2031)
11.2 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025)
11.4 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Novartis AG
12.1.1 Novartis AG Company Information
12.1.2 Novartis AG Business Overview
12.1.3 Novartis AG Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.1.4 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.1.5 Novartis AG Recent Developments
12.2 Merck & Co Inc
12.2.1 Merck & Co Inc Company Information
12.2.2 Merck & Co Inc Business Overview
12.2.3 Merck & Co Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.2.4 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.2.5 Merck & Co Inc Recent Developments
12.3 AbbVie Inc
12.3.1 AbbVie Inc Company Information
12.3.2 AbbVie Inc Business Overview
12.3.3 AbbVie Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.3.4 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.3.5 AbbVie Inc Recent Developments
12.4 Sun Pharma Advanced Research Company Ltd
12.4.1 Sun Pharma Advanced Research Company Ltd Company Information
12.4.2 Sun Pharma Advanced Research Company Ltd Business Overview
12.4.3 Sun Pharma Advanced Research Company Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.4.4 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.4.5 Sun Pharma Advanced Research Company Ltd Recent Developments
12.5 Promedior Inc
12.5.1 Promedior Inc Company Information
12.5.2 Promedior Inc Business Overview
12.5.3 Promedior Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.5.4 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.5.5 Promedior Inc Recent Developments
12.6 NS Pharma Inc
12.6.1 NS Pharma Inc Company Information
12.6.2 NS Pharma Inc Business Overview
12.6.3 NS Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.6.4 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.6.5 NS Pharma Inc Recent Developments
12.7 MEI Pharma Inc
12.7.1 MEI Pharma Inc Company Information
12.7.2 MEI Pharma Inc Business Overview
12.7.3 MEI Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.7.4 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.7.5 MEI Pharma Inc Recent Developments
12.8 MedImmune LLC
12.8.1 MedImmune LLC Company Information
12.8.2 MedImmune LLC Business Overview
12.8.3 MedImmune LLC Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.8.4 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.8.5 MedImmune LLC Recent Developments
12.9 JW Pharmaceutical Corp
12.9.1 JW Pharmaceutical Corp Company Information
12.9.2 JW Pharmaceutical Corp Business Overview
12.9.3 JW Pharmaceutical Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.9.4 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.9.5 JW Pharmaceutical Corp Recent Developments
12.10 Italfarmaco SpA
12.10.1 Italfarmaco SpA Company Information
12.10.2 Italfarmaco SpA Business Overview
12.10.3 Italfarmaco SpA Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.10.4 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.10.5 Italfarmaco SpA Recent Developments
12.11 Incyte Corp
12.11.1 Incyte Corp Company Information
12.11.2 Incyte Corp Business Overview
12.11.3 Incyte Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.11.4 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.11.5 Incyte Corp Recent Developments
12.12 Gilead Sciences Inc
12.12.1 Gilead Sciences Inc Company Information
12.12.2 Gilead Sciences Inc Business Overview
12.12.3 Gilead Sciences Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.12.4 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.12.5 Gilead Sciences Inc Recent Developments
12.13 F. Hoffmann-La Roche Ltd
12.13.1 F. Hoffmann-La Roche Ltd Company Information
12.13.2 F. Hoffmann-La Roche Ltd Business Overview
12.13.3 F. Hoffmann-La Roche Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.13.4 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.13.5 F. Hoffmann-La Roche Ltd Recent Developments
12.14 CTI BioPharma Corp
12.14.1 CTI BioPharma Corp Company Information
12.14.2 CTI BioPharma Corp Business Overview
12.14.3 CTI BioPharma Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.14.4 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.14.5 CTI BioPharma Corp Recent Developments
12.15 Celgene Corp
12.15.1 Celgene Corp Company Information
12.15.2 Celgene Corp Business Overview
12.15.3 Celgene Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
12.15.4 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
12.15.5 Celgene Corp Recent Developments
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Type (2020-2025) & (US$ Million)
Table 6. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type (2020-2025)
Table 7. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 8. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type (2026-2031)
Table 9. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application (2020-2025) & (US$ Million)
Table 10. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2020-2025)
Table 11. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 12. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2026-2031)
Table 13. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 14. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2020-2025) & (US$ Million)
Table 15. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region (2020-2025)
Table 16. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 17. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region (2026-2031)
Table 18. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
Table 19. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Drivers
Table 20. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Opportunities and Challenges
Table 21. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Restraints
Table 22. Global Top Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players by Revenue (US$ Million) & (2020-2025)
Table 23. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Players (2020-2025)
Table 24. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Players Ranking, 2023 VS 2024 VS 2025
Table 25. Global Key Players of Post-Polycythemia Vera Myelofibrosis (PPV-MF), Headquarters and Area Served
Table 26. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025) & (US$ Million)
Table 32. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
Table 33. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 34. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025) & (US$ Million)
Table 35. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
Table 36. Asia Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 37. Asia Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2020-2025) & (US$ Million)
Table 38. Asia Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
Table 39. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 40. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025) & (US$ Million)
Table 41. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
Table 42. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2026-2031) & (US$ Million)
Table 45. Novartis AG Company Information
Table 46. Novartis AG Business Overview
Table 47. Novartis AG Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 48. Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 49. Novartis AG Recent Developments
Table 50. Merck & Co Inc Company Information
Table 51. Merck & Co Inc Business Overview
Table 52. Merck & Co Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 53. Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 54. Merck & Co Inc Recent Developments
Table 55. AbbVie Inc Company Information
Table 56. AbbVie Inc Business Overview
Table 57. AbbVie Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 58. AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 59. AbbVie Inc Recent Developments
Table 60. Sun Pharma Advanced Research Company Ltd Company Information
Table 61. Sun Pharma Advanced Research Company Ltd Business Overview
Table 62. Sun Pharma Advanced Research Company Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 63. Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 64. Sun Pharma Advanced Research Company Ltd Recent Developments
Table 65. Promedior Inc Company Information
Table 66. Promedior Inc Business Overview
Table 67. Promedior Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 68. Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 69. Promedior Inc Recent Developments
Table 70. NS Pharma Inc Company Information
Table 71. NS Pharma Inc Business Overview
Table 72. NS Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 73. NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 74. NS Pharma Inc Recent Developments
Table 75. MEI Pharma Inc Company Information
Table 76. MEI Pharma Inc Business Overview
Table 77. MEI Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 78. MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 79. MEI Pharma Inc Recent Developments
Table 80. MedImmune LLC Company Information
Table 81. MedImmune LLC Business Overview
Table 82. MedImmune LLC Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 83. MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 84. MedImmune LLC Recent Developments
Table 85. JW Pharmaceutical Corp Company Information
Table 86. JW Pharmaceutical Corp Business Overview
Table 87. JW Pharmaceutical Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 88. JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 89. JW Pharmaceutical Corp Recent Developments
Table 90. Italfarmaco SpA Company Information
Table 91. Italfarmaco SpA Business Overview
Table 92. Italfarmaco SpA Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 93. Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 94. Italfarmaco SpA Recent Developments
Table 95. Incyte Corp Company Information
Table 96. Incyte Corp Business Overview
Table 97. Incyte Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 98. Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 99. Incyte Corp Recent Developments
Table 100. Gilead Sciences Inc Company Information
Table 101. Gilead Sciences Inc Business Overview
Table 102. Gilead Sciences Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 103. Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 104. Gilead Sciences Inc Recent Developments
Table 105. F. Hoffmann-La Roche Ltd Company Information
Table 106. F. Hoffmann-La Roche Ltd Business Overview
Table 107. F. Hoffmann-La Roche Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 108. F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 109. F. Hoffmann-La Roche Ltd Recent Developments
Table 110. CTI BioPharma Corp Company Information
Table 111. CTI BioPharma Corp Business Overview
Table 112. CTI BioPharma Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 113. CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 114. CTI BioPharma Corp Recent Developments
Table 115. Celgene Corp Company Information
Table 116. Celgene Corp Business Overview
Table 117. Celgene Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025) & (US$ Million)
Table 118. Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
Table 119. Celgene Corp Recent Developments
Table 120. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Image
Figure 5. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 6. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Type: 2024 VS 2031
Figure 7. Idelalisib Product
Figure 8. Givinostat Product
Figure 9. Glasdegib Product
Figure 10. Durvalumab Product
Figure 11. IMG-7289 Product
Figure 12. Others Product
Figure 13. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application (2025-2031) & (US$ Million)
Figure 14. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Application: 2024 VS 2031
Figure 15. Hospital Product
Figure 16. Clinic Product
Figure 17. Others Product
Figure 18. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 19. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 20. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region: 2024 VS 2031
Figure 21. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Players in 2024
Figure 22. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Manufacturers Established Date
Figure 23. Global Top 5 and 10 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Market Share by Revenue in 2024
Figure 24. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 25. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
Figure 27. United States Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
Figure 30. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
Figure 32. Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
Figure 42. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
Figure 47. Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. China Taiwan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Country (2020-2031)
Figure 52. Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Novartis AG Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 58. Merck & Co Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 59. AbbVie Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 60. Sun Pharma Advanced Research Company Ltd Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 61. Promedior Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 62. NS Pharma Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 63. MEI Pharma Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 64. MedImmune LLC Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 65. JW Pharmaceutical Corp Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 66. Italfarmaco SpA Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 67. Incyte Corp Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 68. Gilead Sciences Inc Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 69. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 70. CTI BioPharma Corp Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
Figure 71. Celgene Corp Revenue Growth Rate in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2020-2025)
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.